Fennec Pharmaceuticals Stock (NASDAQ:FENC)
Previous Close
$5.01
52W Range
$3.96 - $10.52
50D Avg
$6.34
200D Avg
$5.74
Market Cap
$145.42M
Avg Vol (3M)
$83.95K
Beta
0.32
Div Yield
-
FENC Company Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IRON | Disc Medicine, Inc. |
| CSBR | Champions Oncology, Inc. |
| MOLN | Molecular Partners AG |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| OLMA | Olema Pharmaceuticals, Inc. |
| OBIO | Orchestra BioMed Holdings, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| JANX | Janux Therapeutics, Inc. |
| HRMY | Harmony Biosciences Holdings, Inc. |